Oy Jurilab Ltd.

Dsm IP Assets B.v.

Ferrosan A.s.

Oy Juvantia Pharma Ltd.

Jukka T Salonen

Jari Kaikkonen

Tomi-Pekka Tuomainen

Marja Marchesani

Markku Koulu

Matti Karvonen

Ullamari Pesonen

Mika Scheinin

Kristiina Nyyss&ouml;nen

Timo A Lakka

Riitta Salonen

Veli-Pekka Valkonen

Jelena Hyppönen

Juha-Matti Aalto

Henrik Enghusen Poulsen

Pekka Uimari

Jussi Kauhanen

Bent H&oslash;jgaard

Pia Alhopuro

Mia Pirskanen

Paula Heinonen

Amir Snapir

Outi Kontkanen

Ricardo Fuentes

Genes, SNP markers and haplotypes of susceptibility or predisposition to T2D and subdiagnosis of T2D and related medical conditions are disclosed. Methods for diagnosis, prediction of clinical course and efficacy of treatments for T2D, obesity and related phenotypes using polymorphisms in the risk genes are also disclosed. The genes, gene products and agents of the invention are also useful for monitoring the effectiveness of prevention and treatment of T2D and related traits. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of T2D. Novel methods for prevention and treatment of metabolic diseases such as T2D based on the disclosed T2D genes, polypeptides and related pathways are also disclosed.

Genes and markers in type 2 diabetes and obesity

This invention is directed to a DNA sequence comprising a nucleotide sequence encoding a variant paraoxonase protein and to said variant paraoxonase protein as well as a method and a kit for detecting a risk of cancer, coronary or cerebrovascular disease, hypertension, type 2 diabetes, dementia, joint arthrosis, cataract, or sensitivity to organophosphorus compounds in a subject, the method comprising isolating genomic DNA from said subject, determining the allelic pattern for the codon 102 of the paraoxonase encoding PON1 gene in the genomic DNA, identification of Ile101Val mutation indicating said risk being increased and for targeting paraoxonase activity modulating therapies. Further this invention relates to transgenic animals comprising a human DNA molecule encoding said variant paraoxonase and to a method of phenotype-targeted gene sequencing.

DNA molecule encoding a variant paraoxonase and uses thereof

This invention relates to a method for detecting a risk of hypertension and for targeting antihypertensive treatment in a subject, the method comprising isolating genomic DNA from said subject, determining the DNA sequence comprising a nucleotide sequence encoding a variant &#x3b1;-adrenoceptor protein.

Method for detecting a risk of hypertension and uses thereof

A pharmaceutical delivery system comprising a slow-release formulation of vitamin C (ascorbic acid) and a plain-release formulation of vitamin E (tocopherol) has been found to raise and maintain the concentrations of these vitamins in the blood plasma to a ratio of approximately 2.2:1. The steady-state concentration and ratio of these antioxidants has been found to be critical in the prevention and treatment of oxidative stress related disorders such as arteriosclerosis and diabetes and neural degenerative disorders such as Alzheimer's Disease.

Pharmaceutical delivery system for vitamin C and vitamin E and use of a combination of vitamin C and E for preventing or treating conditions involving oxidative stress

This invention relates to a DNA sequence comprising a nucleotide sequence encoding a variant &agr; -adrenoceptor protein and to the variant &agr; -adrenoceptor protein as well as a method for screening a subject to determine if the subject is a carrier of a variant gene that encodes the variant &agr; -adrenoceptor protein. Further this invention relates to a method for treating a mammal suffering from vascular contraction of coronary arteries, the method comprising the step of administering a selective &agr; -adrenoceptor antagonist to the mammal and to transgenic animals comprising a human DNA molecule encoding human &agr; -adrenoceptor protein or the variant &agr; -adrenoceptor protein.

DNA molecule encoding a variant &agr;2B-adrenoceptor protein, and uses thereof

The present invention is directed to a method and a kit for detecting a risk of cancer and coronary heart disease in a subject, comprising isolating genomic DNA from said subject, determining the allelic pattern for the codon 54 of the paraoxonase encoding PON1 gene in the genomic DNA, identification of M54L mutation indicating said risk being reduced.

Method for detecting a risk of cancer and coronary heart disease and kit therefor

Growing community of inventors

Jännevirta, Finland

Jukka T Salonen